Brentuximab Vedotin (BV, SNG35) is an antibody drug-conjugated against CD30 molecule. It consists of a chimeric monoclonal anti CD30 antibody, which by binding CD30 extracellular domains, allows a chemotherapeutic agent, monomethyl auristatin E (MME) to penetrate neoplastic cells. This causes apoptosis of the neoplastic cells, by arresting the cell cycle in G2/M phase1 . Recent clinical trials have shown BV's efficacy in CD30 positive mycosis fungoides (MF) with an objective global response of 56·3%1,2,3 . This article is protected by copyright. All rights reserved.